(Information sent by the signatory company)
– The strategic alliance aims to promote collaboration with researchers working on various diseases through the use of the most powerful PCR technology for diagnosis.
– The companies will facilitate cooperation at the highest level by strengthening collaboration in the SG OneSystemTM project (Seegene’s technology exchange project).
SEOUL, South Korea, May 22, 2024 /PRNewswire/ — Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced on May 16 the signing of a strategic agreement with Springer Nature, the publisher of the prestigious scientific journal Nature.
The reason for this alliance is the common values shared by Springer Nature and Seegene contributing to the advancement of science to achieve a disease-free world.
In the new alliance, the two companies will contribute their experience and knowledge to help researchers in the global scientific community accelerate PCR diagnostic tests for diseases.
PCR molecular diagnostics companies may develop only a few diagnostic products per year. The strategic alliance of Springer Nature and Seegene will provide funding and technology to global scientists and experts in various fields, significantly expanding the range and potential of diagnostic products. This initiative, led by the senior management of both companies, is based on the success of the “Open Innovation” Program, which was launched in 2023, with the aim of developing innovative diagnostic products in collaboration with the scientific community.
Both companies will expand their collaboration through the OneSystemTM project by identifying and promoting potential partners, as well as with a joint statement to sponsor annual symposia.
“We are delighted to strengthen our strategic relationship with Springer Nature, an authority in the global scientific community,” said Dr. Jong-Yoon Chun, CEO and founder of Seegene. “Together, we will work to promote the success of the SG OneSystemTM project and make ‘a disease-free world’ a reality.”
“Springer Nature applauds Seegene’s effort to democratize early diagnosis of multiple diseases for appropriate treatment,” said Frank Vrancken Peeters, CEO of Springer Nature. “This noble goal can only be achieved through collaborations. As a trusted partner of the research community, Springer Nature will help build a global network of experts who, using Seegene technology, can accelerate the development of new assays for a wide range of diseases.”
Seegene and Springer Nature sparked great interest in the global scientific community with the “Open Innovation” Program launched in 2023. The program, which includes 15 projects, received a total of 281 applications from 47 countries, resulting in the election of 1 project for every 11 for the selection of 26 applicants. Recognizing the great potential of technology exchange, the two companies intend to accelerate the placing on the market of the experience and knowledge in various fields accumulated over so many years. This year is the second edition of the program, which will be different than 2023, where product development was predefined. The 2024 program will adopt a more open format, allowing applicants to propose any product development.
“We have high expectations that the Open Innovation Program will contribute to the democratization of molecular diagnostics by PCR,” said Marc Spenlé, COO of Springer Nature. “Together with Seegene, we will create an ecosystem that fosters and accelerates the development of new assays to address current unsolved problems.”
About Seegene
Seegene has 23 years of dedicated R&D, manufacturing and business experience around syndromic quantitative PCR technologies, which stood out during the COVID-19 pandemic when it provided more than 340 million COVID-19 tests to more than 100 countries in everyone. The main feature of Seegene’s unique syndromic PCR technologies is the ability to simultaneously test 14 pathogens causing similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with disease severity.
About Springer Nature
For more than 180 years, Springer Nature has been advancing discovery by providing the best possible service to the entire research community. We help researchers discover new ideas, we ensure that all the research we publish is meaningful, robust and stands up to objective scrutiny, that it reaches all relevant audiences in the best possible format and that it can be discovered, accessed, used, reused and be shared. We support librarians and institutions with innovations in technology and data; and we provide quality editorial support to societies.
As a research publisher, Springer Nature is home to trusted brands such as Springer, Nature Portfolio, BMC, Palgrave Macmillan and Scientific American.
For more information, visit springernature.com and @SpringerNature.
MORE INFORMATION
SG OneSystemTM
The SG OneSystemTM business is Seegene’s global strategy to share its PCR molecular diagnostics technology and knowledge, accumulated over more than 20 years, with leading companies around the world to create a global consortium that would expand Seegene’s product development portfolio. PCR. Additionally, Seegene seeks to leverage the collective experience and knowledge of the global scientific community to promote innovation in the field of diagnostics. Through these combined efforts, the commercialization of experience and knowledge, as well as the development of diagnostic products designed to meet the needs of the local market, SG OneSystemTM aims to democratize early access to PCR tests and ultimately contribute to make ‘a disease-free world’ a reality.’
In January 2024, Seegene entered into a strategic collaboration with Microsoft to strengthen its Seegene Digital Development System (SGDDS) using Microsoft technology, including plans to use artificial intelligence (AI) in the future. Seegene’s collaboration with Microsoft and Springer Nature will boost SG OneSystemTM business. These three companies are planning a declaration event to kick off the collaborative partnerships this year.
Open Innovation Program (OIP)
Open Innovation Program (OIP) is a global PCR reagent development project jointly sponsored by Seegene and Springer Nature. The program launched in September 2023, soliciting proposals from scientists and experts across the community to investigate the 15 projects designated for the development of Seegene’s syndromic qPCR diagnostic reagents.
The open innovation program is part of Seegene’s technology exchange project, SG OneSystemTM, which aims to make a disease-free world a reality by developing products that consolidate the knowledge and experience of science and experts from around the world. world.
Seegene Digitized Development System (SGDDS)
Seegene Digitalized Development System (SGDDS) is a system that enables standardized and automated development of diagnostic kits. It is integrated with Seegene’s technologies and product expertise and provides support for researchers to easily develop syndromic PCR products, even for those with limited development experience.
Photo – https://mma.prnewswire.com/media/2414378…
Logo – https://mma.prnewswire.com/media/1357790…
View original content: https://www.prnewswire.com/news-releases/seegene-y-springer-nature-anuncian-una-alianza-estrategica-302152756.html
